Applied Therapeutics, Inc. (NASDAQ:APLT) CEO Sells $709,174.63 in Stock

Applied Therapeutics, Inc. (NASDAQ:APLT) CEO Shoshana Shendelman sold 119,591 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $5.93, for a total transaction of $709,174.63. Following the completion of the sale, the chief executive officer now directly owns 4,690,839 shares of the company’s stock, valued at approximately $27,816,675.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Shoshana Shendelman also recently made the following trade(s):

• On Monday, August 12th, Shoshana Shendelman sold 300,000 shares of Applied Therapeutics stock. The shares were sold at an average price of $5.98, for a total transaction of $1,794,000.00.
• On Thursday, June 6th, Shoshana Shendelman sold 61,795 shares of Applied Therapeutics stock. The shares were sold at an average price of $4.32, for a total transaction of $266,954.40.

Applied Therapeutics Price Performance

Shares of NASDAQ APLT traded down $0.23 during midday trading on Wednesday, reaching $5.92. 879,444 shares of the stock were exchanged, compared to its average volume of 1,502,755. The business has a 50-day simple moving average of $5.15 and a two-hundred day simple moving average of $5.04. The company has a market capitalization of $676.46 million, a price-to-earnings ratio of -3.22 and a beta of 1.99. Applied Therapeutics, Inc. has a 12 month low of $1.18 and a 12 month high of $9.39.

Institutional Investors Weigh In On Applied Therapeutics

Several institutional investors have recently added to or reduced their stakes in APLT. Janus Henderson Group PLC lifted its position in Applied Therapeutics by 198.6% in the 1st quarter. Janus Henderson Group PLC now owns 6,414,642 shares of the company’s stock valued at $43,555,000 after acquiring an additional 4,266,179 shares in the last quarter. Vestal Point Capital LP bought a new stake in Applied Therapeutics in the 4th quarter valued at $13,919,000. StemPoint Capital LP lifted its position in Applied Therapeutics by 122.3% in the 1st quarter. StemPoint Capital LP now owns 2,017,016 shares of the company’s stock valued at $13,716,000 after acquiring an additional 1,109,864 shares in the last quarter. Artal Group S.A. bought a new stake in Applied Therapeutics in the 1st quarter valued at $6,865,000. Finally, AIGH Capital Management LLC lifted its position in Applied Therapeutics by 109.1% during the 4th quarter. AIGH Capital Management LLC now owns 1,659,039 shares of the company’s stock worth $5,558,000 after buying an additional 865,689 shares in the last quarter. 98.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on APLT. William Blair began coverage on shares of Applied Therapeutics in a report on Wednesday, July 31st. They issued an “outperform” rating for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $12.00 price target on shares of Applied Therapeutics in a report on Wednesday, July 17th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $11.00.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.